H. pylori infection linked to 22% of global colorectal cancer cases, new analysis finds
A new meta-analysis estimates that Helicobacter pylori, a common stomach bacterium, contributes to roughly 22% of global colorectal cancer cases. The study found that H. pylori infection increases the risk of developing colorectal cancer by 59%. While the bacteria is already known to cause stomach cancer and ulcers, this research suggests it may play a significant role in bowel cancer, potentially offering new avenues for prevention through screening and treatment programs.
Key points
- H. pylori infection is associated with a 59% higher risk of developing colorectal cancer.
- The analysis estimates that 22% of global colorectal cancer cases may be linked to H. pylori exposure.
- The study reviewed 43 studies involving 48.7 million people to assess the global burden of H. pylori-related colorectal cancer.
- Researchers suggest that screening and treatment programs for H. pylori could help reduce colorectal cancer incidence, particularly in high-prevalence regions.
- Further high-quality, prospective studies are needed to confirm whether H. pylori eradication therapy reduces colorectal cancer risk.
Background
Recent studies have highlighted various factors contributing to colorectal cancer, including the rising incidence in younger populations and the impact of ultra-processed foods. Additionally, alcohol consumption has been linked to increased colorectal cancer deaths in the US. This new finding adds H. pylori to the list of modifiable risk factors, emphasizing the potential for prevention through existing infection control strategies.
Why it matters
Identifying H. pylori as a significant contributor to colorectal cancer could lead to more effective prevention strategies. Since H. pylori infections are common and treatable with antibiotics, expanding screening and treatment programs could potentially reduce the global burden of colorectal cancer, especially in regions with limited resources. This underscores the importance of integrating infectious disease control into cancer prevention efforts.
What to watch
Researchers call for high-quality, prospective studies with long-term follow-up to determine whether H. pylori eradication therapy can reduce the risk of colorectal cancer. Additionally, there is a need to balance the benefits of such programs against concerns about antibiotic resistance. Further research will be crucial to establish a definitive causal link and to develop targeted prevention strategies.
Want the full story? Read the original reporting
Read on Gizmodo